Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CLEC2A antibody

CLEC2A Reactivity: Human ELISA, IHC Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN7340081
  • Target See all CLEC2A Antibodies
    CLEC2A (C-Type Lectin Domain Family 2, Member A (CLEC2A))
    Reactivity
    • 12
    • 1
    Human
    Host
    • 12
    Rabbit
    Clonality
    • 12
    Polyclonal
    Conjugate
    • 7
    • 1
    • 1
    • 1
    • 1
    • 1
    This CLEC2A antibody is un-conjugated
    Application
    • 11
    • 8
    • 2
    • 2
    • 1
    ELISA, Immunohistochemistry (IHC)
    Cross-Reactivity
    Human
    Purification
    Antigen affinity purification
    Immunogen
    Synthetic peptide of Human CLEC2A
    Isotype
    IgG
  • Application Notes
    ELISA:1:2000-1:5000, IHC:1:50-1:200,
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    -20 °C, pH 7.4 PBS, 0.05 % Sodium azide, 40 % Glycerol
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    -20 °C,-80 °C
    Storage Comment
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Target
    CLEC2A (C-Type Lectin Domain Family 2, Member A (CLEC2A))
    Alternative Name
    CLEC2A (CLEC2A Products)
    Synonyms
    KACL antibody, PILAR antibody, UNQ5792 antibody, CLEC2A antibody, C-type lectin domain family 2 member A antibody, CLEC2A antibody, LOC100847268 antibody, LOC101102719 antibody
    Background

    Background: CLEC2A belongs to the CLEC2 family of activation-induced, natural killer gene complex-encoded C-type lectin-like receptors

    Aliases: C-type lectin domain family 2 member A antibody, CLC2A_HUMAN antibody, CLEC2A antibody, INPE5792 antibody, KACL antibody, Keratinocyte-associated C-type lectin antibody, PILAR antibody, Proliferation-induced lymphocyte-associated receptor antibody, UNQ5792 antibody

    UniProt
    Q6UVW9
You are here: